NCT05111444 is a Phase 2 clinical trial of Camrelizumab in Gastric Neoplasms, sponsored by Fudan University.

Who is sponsoring NCT05111444?

NCT05111444 is sponsored by Fudan University.

What drugs are being tested in NCT05111444?

Interventions in NCT05111444: Camrelizumab, Pyrotinib, Capecitabine, Oxaliplatin, Paclitaxel, S-1.

What condition does NCT05111444 study?

NCT05111444 studies Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma.

Is NCT05111444 still recruiting?

NCT05111444 is currently status unknown. Last updated 8 November 2021.

Last reviewed 2021-11-08 · How we verify

NCT05111444

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Status unknown Phase 2 Last updated 8 November 2021

What this trial tests

Phase 2 trial testing Camrelizumab in Gastric Neoplasms in 65 participants. Status unknown.

Timeline

31 December 2021

Primary endpoint
31 December 2023

30 June 2024

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	65
Start date	31 December 2021
Primary completion	31 December 2023
Estimated completion	30 June 2024
Sites	1 location across China

Drugs / interventions tested

Camrelizumab
Pyrotinib
Capecitabine (capecitabine) — full drug profile →
Oxaliplatin (Oxaliplatin) — full drug profile →
Paclitaxel — full drug profile →
S-1 — full drug profile →

Conditions studied

Gastric Neoplasms — all drugs for Gastric Neoplasms →
Gastroesophageal Junction Adenocarcinoma — all drugs for Gastroesophageal Junction Adenocarcinoma →

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with Gastric Neoplasms or Gastroesophageal Junction Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is designed to evaluate the efficacy and safety of Camrelizumab plus pyrotinib in combination with chemotherapy in patients with HER2-positive gastric cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

HER2-targeted therapies in cancer: a systematic review.
Zhu K, Yang X, Tai H, Zhong X, et al · · 2024 · cited 83× · PMID 38308374 · DOI 10.1186/s40364-024-00565-1
Human Epidermal Growth Factor Receptor-2 Gastric Adenocarcinoma: Expanding Therapy of a Recognized Target.
Rogers JE, Yamashita K, Sewastjanow-Silva M, Trail A, et al · · 2023 · cited 5× · PMID 37958354 · DOI 10.3390/cancers15215180

Verify or expand the search:

Other trials of Camrelizumab

Trials testing the same drug.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07521605 — Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer · Phase 2 · not yet recruiting
NCT07466901 — A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Rad · NA · not yet recruiting
NCT07527026 — A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant T · Phase 2 · recruiting
NCT07266350 — A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for th · not yet recruiting

Other recruiting trials for Gastric Neoplasms

Currently open trials in the same condition.

NCT06848400 — Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios · NA · recruiting
NCT05152147 — A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanc · Phase 3 · active not recruiting
NCT05551416 — The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer · recruiting
NCT01915225 — Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05111444 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 8 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05111444.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing